Technical Data
T9160-10K
Tumor Necrosis Factor alpha, Recombinant, Human (TNFa, Cachectin, TNF-alpha, Tumor Necrosis Factor Ligand Superfamily Member 2, TNF-a, TNF, TNFSF2)
20ug
Growth Factors, Cytokines Storage: -20CShipping: Blue Ice
Tumor necrosis factor-a (TNF-a) is a pleiotropic pro-inflammatory cytokine produced mainly by activated macrophages and in smaller amounts by several other types of cell. TNF-a has been isolated and characterized from a large number of mammals and fish species. TNF-a is expressed in two different forms: a soluble. Mature 17kD form and a transmembrane 26kD form. TNF-a interacts with two distinct cell-surface receptors : Tumor necrosis factor receptor 1(TNFR1) and TNFR2. these mediate the cellular actions. The actions of TNF-a are diverse and profound involving inflammation, apoptosis, cell proliferation and the stimulation of various aspects within the immune system. TNF-a is increasingly recognized as a key regulator of lipid metabolism in adipose tissue and protein catabolism in muscle and in disease states such as cancer, Acquired Immune Deficiency Syndrome (AIDS) and obesity-related insulin resistance.

Source:
Recombinant corresponding to aa77-23, from human TNF-a, expressed in E.coli.

Molecular Weight:
~17.5kD

Endotoxin Level:
0.05EU/ug

Specific Activity:
The ED50 as determined by the cytolysis of murine L929cells in the presense of actinomycin D is 0.03-0.06 ng/ml.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Molecular Weight:
~17.5kD
Source: E.coli
Purity: ~98% (SDS-PAGE)
Concentration: As reported
Form: Supplied as a liquid in 20mM Tris, pH 8.0, 1mM EDTA, 10% glycerol.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Wen-Xing Ding et al (2004) J.Cell. Mol. Med 8(4);445-454. 2. Sudhir Gupta (2002) Journal of Clinical Immunology 22(4);185-194. 3. Frederick W. goetz et al (2004) Developmental and comparative Immunology 28;487-497. 4. Havell, E.A. (1987) J. Immunol. 39:4225-4231.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.